– Discoveries support next phase of collaboration with AbbVie –

 Cambridge, Mass (Business Wire) – Synlogic™ has completed the first phase of its ongoing collaboration with AbbVie. During this first discovery phase of the collaboration Synlogic has identified Synthetic Biotic™ leads for the treatment of inflammatory bowel disease (IBD), including Crohn’s Disease and colitis, using the company’s proprietary discovery and development technology platform. Based on the terms of the agreement, Synlogic will receive an undisclosed milestone payment and the companies will move into the second phase of the collaboration. Synlogic is pioneering the development of a novel class of living medicines – Synthetic Biotic™ medicines, which perform critical functions or deliver therapeutic factors to compensate for what is missing or damaged due to disease.

“The delivery of these investigational Synthetic Biotic medicines, as part of the first phase of our collaboration with AbbVie, demonstrates the continued potential of our discovery and development platform against a wide range of diseases,” said Jose Carlos Gutierrez-Ramos, Ph.D., president and chief executive officer of Synlogic. “We believe our living medicines have the potential to be transformational for patients, and our commitment to advance the platform’s power includes pursuing innovative partnerships such as the one we’ve forged with AbbVie.”

Under the terms of the ongoing research and development collaboration, AbbVie and Synlogic will continue to evaluate the investigational Synthetic Biotic leads as potential candidates for the treatment of IBD and advance them through preclinical development, with AbbVie having a right to subsequent clinical development and worldwide marketing of resulting products. Further detail on the terms of the deal were not disclosed.

About the Synthetic Biotic™ Platform

Synlogic has developed a proprietary drug discovery and development platform for creation of an innovative new class of living medicines called Synthetic Biotics. The company deploys the tools and principles of synthetic biology to genetically reengineer beneficial, probiotic microbes to perform critical functions missing or damaged due to disease. Once engineered, Synthetic Biotic medicines are capable of “replacing” what a patient’s body cannot do with their own somatic organs due to their disease state, such as producing or consuming an enzyme or protein critical to health. These living medicines can be designed to dynamically sense and respond to their environment for a tailored effect and can also function catalytically where a single engineered cell can carry out multiple cycles of the intended pathway activity. Synlogic is developing Synthetic Biotic medicines for rare metabolic disease and actively seeking new partnership opportunities for more common disorders.

About Synlogic™

Synlogic™ is pioneering the development of a novel class of living medicines, Synthetic Biotics™, based on its proprietary drug discovery and development platform. Synlogic’s initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer.

Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit synlogictx.com.

 Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic’s platform to develop therapeutics to address a wide range of diseases, including IBD, and the continued preclinical development of Synthetic Biotic leads pursuant to the AbbVie collaboration. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, the uncertainties inherent in the preclinical development process, the ability of Synlogic to protect its intellectual property rights and legislative, regulatory, political and economic developments.

Contacts

MEDIA:
Synlogic
Courtney Heath, 617-872-2462
courtney@scientpr.com

INVESTORS:
Synlogic
Christina Tartaglia, 212-362-1200
christina@sternir.com